Kowsar Semnan Research and Medical Training Center
Semnan, 3514799442, Iran
NCT Number: NCT04932213
The aim of this study is to compare the effect of tropicamide 0.5% and tropicamide 1% on intraocular pressure and anterior chamber parameters in patients with Diabetes Mellitus.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Phase 3
Semnan, 3514799442, Iran
Patients with diabetes type 1 and type 2 older than 21 years of age, in the specialized clinic of Kowsar Hospital (Semnan University of Medical Sciences) are examined. Eligible individuals enter the study and are randomly assigned to group 1 or group 2. In each group, visual acuity measurement, slit lamp biomicroscopy and fundus examination are performed. Intraocular pressure is measured with Goldmann applanation tonometer. pupil size, refraction and keratometry are measured with two different autorefractokeratometers. keratometry, pupil size and other anterior chamber parameters are also evaluated by Oculus Pentacam imaging. Then, the patients receive tropicamide 0.5% drops in group 1 and tropicamide 1% drops in group 2. 30 minutes later, all previous measurements are repeated. Patients and the ophthalmologist and the data analyzer are unaware of the drug type.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
Other names: Mydrax (Sina Darou)
Time frame: Before intervention, 30 minutes after intervention
The intraocular pressure is measured by Goldmann applanation tonometry
Time frame: Before intervention, 30 minutes after intervention
The diameter of the participants' pupil is measured by Scheimpflug camera (Oculus Pentacam); Autorefractokeratometer (TOMEY RC-5000 and Topcon KR-1)
Time frame: Before intervention, 30 minutes after intervention
The keratometry is obtained by Scheimpflug camera (Oculus Pentacam); Autorefractokeratometer (TOMEY RC-5000 and Topcon KR-1)
Time frame: Before intervention, 30 minutes after intervention
The ACD is measured by Scheimpflug camera (Oculus Pentacam)
Time frame: Before intervention, 30 minutes after intervention
The ACV is measured by Scheimpflug camera (Oculus Pentacam)
Time frame: Before intervention, 30 minutes after intervention
The ACA is measured by Scheimpflug camera (Oculus Pentacam)
Time frame: Before intervention, 30 minutes after intervention
The CCT is measured by Scheimpflug camera (Oculus Pentacam)
Semnan University of Medical Sciences
Other
Comparison of the Effect of Tropicamide 0.5% and Tropicamide 1% on Intraocular Pressure, Pupil Size, Keratometry and Anterior Chamber Parameters in Patients With Type 1 and Type 2 Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05144802
Autoimmune Diseases, Diabetes Mellitus
Poitiers, France
View Trial DetailsNCT05018416
Autoimmune Diseases, Chronic Disease
Denver, Colorado, United States
View Trial DetailsNCT00639964
Autoimmune Diseases, Diabetes Mellitus
Lille, France
View Trial DetailsNCT04429503
Autoimmune Diseases, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial Details